Breast cancer home injections: Convenient for patients, complex for insurers
Despite the clinical benefits of home-based breast cancer therapy, insurance policies frequently impede patient access to these convenient injection programs.
Multicancer early detection: Can we screen for what we can't treat?
An FDA advisory panel has supported the clinical utility of multicancer early detection (MCED) tests, marking a potential shift in cancer screening paradigms.
Salivary gland cancer: Is HER2-low the new HER2-positive?
Trastuzumab rezetecan demonstrated antitumor activity in advanced salivary gland carcinoma, particularly in HER2-high disease, with a 50% objective response rate.
Chemo hair loss: Why some patients feel it more deeply
Olaparib: Why HRD in breast and ovarian cancer goes beyond BRCA
Why are we still treating cancer prevention as adjunctive care?
Lung cancer in never smokers: The 60x risk factor you might be missing
Multicancer tests: Can we screen without knowing the outcome?
Brain metastases: Why less radiation, more often, improves outcomes
Pruritus in primary biliary cholangitis: the symptom that drives quality of life
Pruritus significantly impacts quality of life in primary biliary cholangitis, driving patient-reported outcomes and necessitating targeted management strategies.
Why primary sclerosing cholangitis remains a therapeutic graveyard
Despite numerous attempts, no disease-modifying therapy has succeeded in primary sclerosing cholangitis, leaving transplant as the only definitive treatment.
Cholangiocarcinoma Surveillance: What Interval, What Modality in PSC?
Annual surveillance for cholangiocarcinoma in primary sclerosing cholangitis patients should include noninvasive imaging and serum CA 19-9, according to expert recommendations.
Seladelpar and elafibranor: second-line options for PBC
MASH: Why diabetes management now demands a liver-first approach?
Seladelpar and Elafibranor: The Second-Line Options for PBC After Ursodeoxycholic Acid Fails
ACLF: Why G-CSF works for some, but fails others
Chronic hepatitis B: Is PD-1 blockade the key to T-cell revival?
Liver disease: Is coffee a daily dose of prevention?
GLP-1s: Is eligibility missing half your high-risk patients?
A 313,000-person Danish and UK analysis finds people with a BMI of 25-26.9, currently ineligible for GLP-1 receptor agonists, have coronary heart disease risk matching those who do qualify, if they also carry elevated remnant cholesterol or inflammation.
Evolocumab: Is LDL-C reduction finally translating to lives saved?
Evolocumab, a PCSK9 inhibitor, has demonstrated a potential to reduce the risk of death in patients at high cardiovascular risk, offering a critical addition to lipid-lowering strategies.
LAA occlusion: Less bleeding, but is stroke risk truly equal?
Left atrial appendage occlusion (LAAO) reduces nonprocedural bleeding in AF patients but shows no difference in stroke or mortality compared to medical therapy.
Endocarditis: Why fixed-dose ampicillin often misses the mark
Rethinking xylitol: Is this 'healthy' sugar substitute a cardiac threat?
Peripheral arterial disease: Why early detection still eludes us
Tactical athletes need more than a sports physical
Hypertension: Do shorter wall squats work as well for older women?
Beyond diagnosis: ECG waveforms predict MI-E treatment response
Rotavirus vaccine and T1D: Is an 11% rise cause for alarm?
Type 1 diabetes incidence in Norwegian children rose 11% after rotavirus vaccination began, but similar rises followed unrelated vaccine changes.
Survodutide: Is 9.8% weight loss enough for its GI cost?
SYNCHRONIZE-2 in NEJM: survodutide 6.0 mg cut weight 9.8% versus 3.9% on placebo over 76 weeks in type 2 diabetes, but about 1 in 4 stopped treatment.
Low-carb diets in kids with type 1 diabetes: safe, but not standard?
In 45,569 children, very low carbohydrate diets were not linked to poorer growth, severe hypoglycaemia or ketoacidosis, though the evidence remains observational.
CBL-514: Is visceral fat reduction the real story?
The 2026 ADA/EASD consensus: Why early SGLT2/GLP-1 works
Type 1 diabetes screening: Why one protocol worked across 8 nations
Bariatric surgery: The hidden hernia risk you're missing
Marathon running with type 1 diabetes: Is it finally safe?
Amylin plus tirzepatide: Is 23% weight loss the new benchmark?
Epilepsy: Is art the missing piece in holistic patient care?
A new exhibit showcases artists living with epilepsy, aiming to reframe public perception of the condition beyond its clinical manifestations.
Routine childhood vaccines: Less coverage means more than just infections
Routine childhood vaccination coverage has stagnated globally, with persistent inequities amplified by the COVID-19 pandemic, raising concerns for future health outcomes.
Brexpiprazole for Alzheimer's agitation: Antidepressants don't change efficacy
A post hoc analysis found brexpiprazole reduced agitation in Alzheimer's dementia, with similar efficacy regardless of concomitant antidepressant use.
Spike sorting: Is your 'black box' holding back neural insights?
Fibromyalgia: Is the pain real if the tissue damage isn't?
Can mice learn to control their own brains? A new neurofeedback system
Lifelong odor sensitivity: What early exposure means for your patients?
Tau: Why its 'knockout' effect is a clue to Alzheimer's
Parkinson's cognitive decline: Is Juvmo the answer we overlooked?
R-CHOP has been standard of care for 20 years. frontMIND may be the beginning of the end
An epidemiological shift in T2D is reshaping drug development and market access for oncology and metabolic portfolios.
The most resistant cancer is finally responding, and the pipeline is accelerating
Lecanemab and donanemab are approved. The harder question is who gets them and how
Label expansion triples the eligible population and the infrastructure race begins
LeukemiaRusfertide and hepcidin mimetics: a different way to control erythrocytosis
Get the full storyHaematocrit targets: Is 45% still the right threshold for phlebotomy?
Get the full storyWhy molecular response in polycythemia vera remains an elusive endpoint
Get the full storyPNH: Beyond Eculizumab, How Proximal Inhibition Reshaped Treatment Goals
Get the full storyWhen complement inhibitors fail: Recognizing breakthrough haemolysis
Get the full storyOral factor B inhibition: a new path for PNH management?
Get the full storyMyelofibrosis: Why transplant timing dictates survival, not just symptoms
Get the full storyChoosing a JAK Inhibitor in Myelofibrosis: Beyond Ruxolitinib
Get the full storyMomelotinib and anaemia in myelofibrosis: a new calculus for treatment?
Get the full storyGene therapy for thalassemia: Approval is one hurdle, access is the next
Get the full story
Idiopathic Pulmonary Fibrosis
Clostridioides difficile
• Oct 21 – 23LIVEESMO 2026 • Madrid, ES 
• Oct 23 – 27ACR 2026 • Orlando, US 
• Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12LIVEJoint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23LIVEESMO 2026 • Madrid, ES • Oct 23 – 27ACR 2026 • Orlando, US • Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12
Advertisement
AdvertisementAdvertisementAdvertisement
TorontoOct 21 – 23 2026Get on-site reporting the moment it publishes.
TorontoAttending Joint ACTRIMS-ECTRIMS 2026?
Get our free prep guide: key sessions by day, satellite symposia listings, and recommended spots near the venue.
Free. No spam. Unsubscribe anytime.
